StreetInsider.com News Articles

Form 8-K MapLight Therapeutics, For: Jun 18

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667081.html

Form 8-K MapLight Therapeutics, For: Jun 18

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667081.html

MapLight Therapeutics (MPLT) PT Raised to $36 at Stifel

Mon, 01 Jun 2026 16:13:28 -0400

Stifel analyst Paul Matteis raised the price target on MapLight Therapeutics (NASDAQ: MPLT) to $36.00 (from $28.00) while maintaining a Buy rating.

The analyst comments "We are reiterating our Buy rating and raising our TP to $36 (vs $28) on MPLT following our recent NDR with CEO Chris Kroeger, CMO Erin Foff, and CFO Vishwas Setia, where we discussed upcoming catalysts. Main takeaways include: (1) MPLT believes ML-007C-MA will be differentiated from Cobenfy with no-fasting requirement and easier titration--at the very least, (2) MPLT's ph1 data support potential QD dosing and/or better tolerability--either would be commercially attractive, (3) better efficacy would

MapLight Therapeutics (MPLT) PT Raised to $36 at Stifel

Mon, 01 Jun 2026 16:13:28 -0400

Stifel analyst Paul Matteis raised the price target on MapLight Therapeutics (NASDAQ: MPLT) to $36.00 (from $28.00) while maintaining a Buy rating.

UBS Starts MapLight Therapeutics (MPLT) at Buy

Tue, 26 May 2026 16:15:11 -0400

UBS initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Buy rating and a price target of $48.00.

For an analyst ratings summary and ratings history on MapLight Therapeutics click here. For more ratings news on MapLight Therapeutics click here.

Shares of MapLight Therapeutics closed at $28.75 yesterday.

Craig-Hallum Starts MapLight Therapeutics (MPLT) at Buy

Thu, 21 May 2026 10:10:42 -0400

Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Buy rating and a price target of $43.00.

The analyst comments "Thoughts on Shares. MPLT represents one of the more differentiated follow-on opportunities within the muscarinic landscape. If successful, we believe this could support meaningful share capture in schizophrenia and broaden the relevance of muscarinic therapies across additional neuropsychiatric indications. At current levels, we view the setup into Ph2 schizophrenia and autism data as favorable given the combination of a clinically validated mechanism, a thoughtful translational strategy, and expectations that remain relatively measure."

For an analyst ratings summary and

Craig-Hallum Starts MapLight Therapeutics (MPLT) at Buy

Thu, 21 May 2026 10:10:42 -0400

Craig-Hallum analyst Adam Vogel initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Buy rating and a price target of $43.00.

For an analyst ratings summary and

Form 4 MapLight Therapeutics, For: May 18 Filed by: Kroeger Christopher A.

Mon, 18 May 2026 21:27:00 -0400

si-local-file:///var/storage/secattach/20260518/26515752.html

Form 4 MapLight Therapeutics, For: May 18 Filed by: Kroeger Christopher A.

Mon, 18 May 2026 21:27:00 -0400

si-local-file:///var/storage/secattach/20260518/26515752.html

Form SCHEDULE 13G/A MapLight Therapeutics, Filed by: T. Rowe Price Investment Management, Inc.

Fri, 15 May 2026 10:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26501262.html

Form SCHEDULE 13G/A MapLight Therapeutics, Filed by: T. Rowe Price Investment Management, Inc.

Fri, 15 May 2026 10:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26501262.html

MapLight Therapeutics, Inc. (MPLT) Misses Q1 EPS by 42c

Fri, 15 May 2026 06:03:57 -0400

MapLight Therapeutics, Inc. (NASDAQ: MPLT) reported Q1 EPS of ($1.34), $0.42 worse than the analyst estimate of ($0.92).

For earnings history and earnings-related data on MapLight Therapeutics, Inc. (MPLT) click here.

Form 10-Q MapLight Therapeutics, For: Mar 31

Thu, 14 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260514/26495530.html

Form 10-Q MapLight Therapeutics, For: Mar 31

Thu, 14 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260514/26495530.html

Form 8-K MapLight Therapeutics, For: May 14

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495205.html

Form 8-K MapLight Therapeutics, For: May 14

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495205.html

MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 16:05:00 -0400

Enrollment completed in ML-007C-MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026
Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism spectrum disorder, with topline results expected by mid-August 2026
Enrollment ongoing in ML-007C-MA’s Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027
Ended the quarter with $395.2 million in cash, cash equivalents and investments, which is expected to fund operations through 2027

SAN FRANCISCO and BOSTON, May 14, 2026 (GLOBE NEWSWIRE) --

MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 16:05:00 -0400

Enrollment completed in ML-007C-MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026
Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism spectrum disorder, with topline results expected by mid-August 2026
Enrollment ongoing in ML-007C-MA’s Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results expected in the second half of 2027
Ended the quarter with $395.2 million in cash, cash equivalents and investments, which is expected to fund operations through 2027

SAN FRANCISCO and BOSTON, May 14, 2026 (GLOBE NEWSWIRE) --

Form 4 MapLight Therapeutics, For: May 07 Filed by: Lillie James Woodruff